Lung Stereotactic Body Radiotherapy: Single-Center Experience

Abstract

OBJECTIVETo evaluate the results of stereotactic body radiotherapy (SBRT) in early-stage lung cancer, lung metastasis,and recurrent lung cancer.METHODSFifty-nine cases that underwent lung SBRT due to early-stage lung cancer, lung metastasis, or lung cancerrecurrence at our Radiation Oncology Department between 2016 and 2019 were retrospectivelyevaluated. The factors affecting overall survival (OS) and progression-free survival (PFS) after SBRTwere investigated.RESULTSAfter SBRT, the median PFS was 12 (0-40) months, whereas OS was 16 (3-44) months. The median durationof OS and PFS were 15 (5-44) and 12.5 (3-40) months, respectively for early-stage lung cancer, 19(3-28) and 12 (0-27) months, respectively for recurrent lung cancer, and 14 (5-25) and 8 (5-25) months,respectively, for lung metastasis. During the 16-month median follow-up after SBRT, eight cases (13.6%)died of cancer, and cancer progressed in 16 cases (27.1%). The factors affecting OS after SBRT were age(p=0.041), KPS (≥80) (p=0.019), and maximum tumor diameter (≤3 cm) (p=0.033) according to univariateanalysis, and KPS (≥80) (p=0.011) and maximum tumor diameter (>3 cm) (p=0.007) according tomultivariate analysis, and the variables affecting PFS after SBRT were GTV (p=0.011) and BED10 (≥100)(p=0.043) for the former, and GTV (p=0.011) for the latter. No patient developed ≥3 radiation pneumonia.CONCLUSIONFollowing lung SBRT, OS was better in younger patients, those with ≥80 KPS or with a tumor diameterof ≤3 cm while PFS was higher in cases with a small GTV volume and those that received BED10≥100radiotherapy dose.